We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PBMs May Be Complicit in Schemes to Curb Price Competition, Gottlieb Says
PBMs May Be Complicit in Schemes to Curb Price Competition, Gottlieb Says
FDA Commissioner Scott Gottlieb said pharmacy benefit managers may be “complacent participants” in schemes to stifle biosimilar competition and raise drug prices by keeping cheaper versions of drugs off the market.